A Multi-Center Study Evaluating the Rate of Genotype 1, 2, 3 and 4 Chronic Hepatitis C Patients With Slow Response / Non-rapid Viral Response to Anti-Viral Treatment of Pegasys (Peginterferon Alfa 2a) in Combination With Copegus (Ribavirin).
Phase of Trial: Phase IV
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 18 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Nov 2013 Status changed from completed to recruiting as reported by ClinicalTrials.gov.